Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer.
J Drugs Dermatol
; 23(4): e102-e103, 2024 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-38564383
ABSTRACT
Inflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using MEK inhibitors, this is the first reported case of inflammatory alopecia. J Drugs Dermatol. 2024;23(4)7802. doi10.36849/JDD.7802e  .
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Ovarianas
/
Alopecia
Limite:
Female
/
Humans
Idioma:
En
Revista:
J Drugs Dermatol
Ano de publicação:
2024
Tipo de documento:
Article